The thrombin generation test is a global test of coagulation. High thrombin generation has been associated with thrombosis, whereas low thrombin generation can result in bleeding episodes. Although the thrombin generation test has been used in the field of thrombosis and hemostasis for several decades now, several technical advances have been recently made in the field of thrombin generation. Whereas thrombin generation used to be an experimental test, the development of fully automated thrombin generation analyzers has introduced thrombin generation into the clinical lab. Additionally, in the research setting, multiple new TG or TG-related techniques are now available, such as the TG test in whole blood, the assessment of pro-and anticoagulant processes during TG (thrombin dynamics method), and the measurement of the sensitivity of the APC system using thrombomodulin.
In this research topic, we aim to provide a platform for researchers to share their data on the clinical and experimental advances in thrombin generation. Thrombin generation is used more and more in the clinic, mainly because of fully automated measurement devices, such as the ST-Genesia. As thrombin generation is now studied in many diseases, we would like to invite researchers to share their findings to support further implementation of the thrombin generation test in the clinic.
We also would like to stimulate the reporting of specialized thrombin generation test protocols designed for specific patient groups, as well as the development and validation of novel TG-based methods. Also, larger studies giving a better understanding of the biological meaning of the TG parameters, particularly prospective studies investigating the predictive capacity of TG for thrombotic events such as stroke and myocardial infarction are welcomed.
Possible topics include, but are not limited to:
1) Clinical studies using thrombin generation (either semi-automated or fully automated) to address a specific clinical question.
2) Development of specialized/adapted thrombin generation test for specific patient populations, including the use of alternative coagulation triggers or the use of experimental calculation methods in addition to the ‘regular’ thrombin generation parameters.
3) The development, use and clinical validation of novel thrombin generation test-based methods, such as whole blood thrombin generation or the thrombin dynamics analysis.
4) The use of thrombin generation in clinical care and clinical decision making, for example, to adjust therapy in hemophilia A or to monitor or adjust the dose in patients on anticoagulants.
5) Prospective studies on the predictive capacity of TG for thrombotic conditions, such as myocardial infarction and stroke.
The thrombin generation test is a global test of coagulation. High thrombin generation has been associated with thrombosis, whereas low thrombin generation can result in bleeding episodes. Although the thrombin generation test has been used in the field of thrombosis and hemostasis for several decades now, several technical advances have been recently made in the field of thrombin generation. Whereas thrombin generation used to be an experimental test, the development of fully automated thrombin generation analyzers has introduced thrombin generation into the clinical lab. Additionally, in the research setting, multiple new TG or TG-related techniques are now available, such as the TG test in whole blood, the assessment of pro-and anticoagulant processes during TG (thrombin dynamics method), and the measurement of the sensitivity of the APC system using thrombomodulin.
In this research topic, we aim to provide a platform for researchers to share their data on the clinical and experimental advances in thrombin generation. Thrombin generation is used more and more in the clinic, mainly because of fully automated measurement devices, such as the ST-Genesia. As thrombin generation is now studied in many diseases, we would like to invite researchers to share their findings to support further implementation of the thrombin generation test in the clinic.
We also would like to stimulate the reporting of specialized thrombin generation test protocols designed for specific patient groups, as well as the development and validation of novel TG-based methods. Also, larger studies giving a better understanding of the biological meaning of the TG parameters, particularly prospective studies investigating the predictive capacity of TG for thrombotic events such as stroke and myocardial infarction are welcomed.
Possible topics include, but are not limited to:
1) Clinical studies using thrombin generation (either semi-automated or fully automated) to address a specific clinical question.
2) Development of specialized/adapted thrombin generation test for specific patient populations, including the use of alternative coagulation triggers or the use of experimental calculation methods in addition to the ‘regular’ thrombin generation parameters.
3) The development, use and clinical validation of novel thrombin generation test-based methods, such as whole blood thrombin generation or the thrombin dynamics analysis.
4) The use of thrombin generation in clinical care and clinical decision making, for example, to adjust therapy in hemophilia A or to monitor or adjust the dose in patients on anticoagulants.
5) Prospective studies on the predictive capacity of TG for thrombotic conditions, such as myocardial infarction and stroke.